ArticleAmerican journal of translational research2025
Significance of lipoprotein a and high-sensitivity CRP combined assay in diagnosing coronary heart disease and their relationship with coronary lesion severity.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic performance of lipoprotein A (LP(a)) and high-sensitivity C-reactive protein (hs-CRP) combined assay for coronary heart disease (CHD) and their association with the severity of coronary lesions.
methodsThis retrospective study included 106 patients who underwent coronary angiography (CAG) due to thoracic distress at Xi'an International Medical Center Hospital from June 2020 to October 2021. The patients were categorized into two groups: the CHD group (n=67) and the non-CHD group (n=39). Subgroup analysis was performed within the CHD group based on the Gensini score. Serum levels of LP(a) and hs-CRP were compared between the groups and subgroups, and their correlations with the Gensini score were analyzed. The diagnostic performance of LP(a), hs-CRP, and their combined assay for detecting CHD was evaluated using receiver operating characteristic (ROC) curve analysis.
resultsSerum levels of LP(a) and hs-CRP were significantly higher in the CHD group than those in the non-CHD group (P<0.001). Within the CHD subgroups, both LP(a) and hs-CRP levels were significantly elevated in the moderate and high Gensini score groups compared to the low Gensini score group (P<0.001). There was a positive correlation between LP(a) and hs-CRP levels with the Gensini score (r=0.288, P=0.003; r=0.276, P=0.004). The area under the ROC curve (AUC) for the combination of LP(a) and hs-CRP (0.924, 95% CI: 0.865-0.983) was significantly greater than that for LP(a) (0.858, 95% CI: 0.783-0.933) or hs-CRP (0.854, 95% CI: 0.772-0.936) alone (P<0.05).
conclusionElevated serum levels of LP(a) and hs-CRP are associated with CHD and correlate with the severity of coronary lesions. The LP(a) and hs-CRP combined assay improves the diagnostic performance for CHD, suggesting potential clinical value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.